{"nctId":"NCT01318733","briefTitle":"Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea","startDateStruct":{"date":"2011-03"},"conditions":["Rosacea"],"count":449,"armGroups":[{"label":"CD07805/47 Gel 0.5%","type":"EXPERIMENTAL","interventionNames":["Drug: CD07805/47 gel 0.5%"]}],"interventions":[{"name":"CD07805/47 gel 0.5%","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female who is at least 18 years of age or older.\n* A clinical diagnosis of facial rosacea.\n* A Clinician Erythema Assessment (CEA) score of ≥3 at Screening and at Baseline (prior to study drug application).\n* A Patient Self Assessment (PSA) score of ≥3 at Screening and at Baseline (prior to study drug application).\n\nExclusion Criteria:\n\n* Particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin) or other concomitant facial dermatoses that are similar to rosacea such as peri-oral dermatitis, demodicidosis, facial keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, or actinic telangiectasia.\n* Current diagnosis of Raynaud's syndrome, thromboangiitis obliterans, orthostatic hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal or hepatic impairment, scleroderma, Sjögren's syndrome, or depression.\n* Previous refractive eye surgery such as photorefractive keratectomy (PRK), laser-assisted sub-epithelial keratectomy (LASEK), or laser-assisted in situ keratomileusis (LASIK).\n* Current treatment with monoamine oxidase (MAO) inhibitors.\n* Current treatment with barbiturates, opiates, sedatives, systemic anesthetics, or alpha-agonists.\n* Less than 3 months stable dose treatment with tricyclic anti-depressants, cardiac glycosides, beta blockers or other antihypertensive agents.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Long Term Safety & Efficacy of CD07805/47 Gel 0.5% in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea.","description":"Static evaluation of erythema severity using the Clinician Erythema Assessment (CEA) - Grade/Description 0 / Clear Skin with no signs of erythema\n\n1. / Almost clear; slight redness\n2. / Mild erythema; definite redness\n3. / Moderate erythema; marked redness\n4. / Severe erythema; fiery redness\n\nChange in CEA from Baseline CEA (T0 at Baseline visit Day 1) at T3 of each post-baseline visit, including Day 1.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":".88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":".85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":".83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":".84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":".88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":".9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":".83"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":449},"commonTop":["Flushing","Erythema","Rosacea"]}}}